Naproxen May Be “Exception” To NSAID Rule, But Data Is Lacking – FDA
This article was originally published in The Tan Sheet
Executive Summary
An FDA memorandum released April 15 points to naproxen as a potentially safer NSAID compared to other drugs in the class
You may also be interested in...
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany